all report title image

GENE AND CELL THERAPIES TARGETING CNS DISORDERS MARKET ANALYSIS

Gene and Cell Therapies Targeting CNS Disorders Market, by Therapy Type (Gene Therapy and Cell Therapy), by Indication (Alzheimer's Disease (AD), Huntington's Disease (HD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease, Multiple Sclerosis (MS), Adrenoleukodystrophy & Metachromatic Leukodystrophy, Neuropathies, and Batten Disease (BD)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Nov 2024
  • Code : CMI4705
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Leading Companies

Global Gene and Cell Therapies Targeting CNS Disorders Market – Competitive landscape

Key players operating in the global gene and cell therapies targeting CNS disorders market include Novartis, BrainStorm Cell Therapeutics, Corestem, Q Therapeutics, Helixmith, Rapa Therapeutics, Neuroplast, StemCyte, Ferrer Internacional, Neuralstem, Ferrer Internacional, Stemedica Cell Technologies, Libella Gene Therapeutics, Sangamo Therapeutics, Hoffmann-La Roche, Longeveron, Sio Gene Therapies, Eli Lilly and Company, NeuroGeneration, Brain Neurotherapy Bio (AskBio), and UniQure Biopharma.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.